Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Information, Expiry & Status of FDA Orange Book Patents covering DSSTox_CID_3143

Client Email

Product

DSSTox_CID_3143
Agomelatine
147086-81-5
US Patents

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

Contact Supplier

xyz-pharma-m-2024-09-09

Contact Supplier

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Contact Supplier

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

xyz-pharma-m-2024-09-09

Contact Supplier

DSSTox_CID_3143

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

25 API Suppliers, 16 USDMF, 3 CEP/COS, 2 JDMF, 2 EU WC, 3 KDMF, 3 NDC API, 6 Listed Suppliers, $ API Reference Price

25 API Suppliers
16 USDMF
3 CEP/COS
2 JDMF
2 EU WC
3 KDMF
3 NDC API
6 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

API Reference Price
API Exports
API Imports
FDF Exports
FDF Imports

INTERMEDIATES

1 API Suppliers

1 API Suppliers

FINISHED DOSAGE FORMULATIONS

47 FDF Dossiers, 13 FDA Orange Book, 10 Europe, 4 Canada, 9 South Africa, 11 Listed Dossiers

47 FDF Dossiers
13 FDA Orange Book
10 Europe
4 Canada
9 South Africa
11 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INTRAVENOUS - EQ 250MG BASE/VIAL;250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER;INTRAVENOUS - EQ 500MG BASE/VIAL;500MG/VIAL

POWDER;INTRAVENOUS - EQ 250MG BASE/VIAL;250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
POWDER;INTRAVENOUS - EQ 500MG BASE/VIAL;500MG/VIAL

RELATED EXCIPIENT COMPANIES

1 SPI Pharma

1 SPI Pharma

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 20 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
20 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 10 Finished Drug Prices, 10 Annual Reports

1 US Medicaid Prescriptions
10 Finished Drug Prices
10 Annual Reports

MARKET PLACE

13 APIs, 4 FDF Dossiers

13 APIs
4 FDF Dossiers

PATENTS & EXCLUSIVITIES

3 US Patents, 2 US Exclusivities

3 US Patents
2 US Exclusivities

REF. STANDARDS & IMPURITIES

1 EDQM, 1 USP, 1 Others

1 EDQM
1 USP
1 Others

$ API Ref.Price (USD/KG) : 1,493 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

3 All

01 3MSD MERCK CO

filter Patent Number Reset all filters

3 All

01 38487093

filter API Patent Reset all filters

3 All

01 3Y

filter FDF Patent Reset all filters

3 All

01 3Y

filter Expiration Date Reset all filters

3 All

01 32033-03-21

US Patents
US Exclusivities

Product Main Page

01

MSD MERCK CO

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Formnext Forum

Not Confirmed

MSD MERCK CO

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-03-21

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

US Patent Number : 8487093

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212819

Patent Use Code : U-2587

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-03-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

MSD MERCK CO

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Formnext Forum

Not Confirmed

MSD MERCK CO

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-03-21

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

US Patent Number : 8487093

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212819

Patent Use Code : U-2840

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-03-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

MSD MERCK CO

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Formnext Forum

Not Confirmed

MSD MERCK CO

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-03-21

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

US Patent Number : 8487093

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212819

Patent Use Code : U-2586

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-03-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?